Home > Technologies > Publications > 2011

Publications

Publications

  • Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG

    Jonsson MK, Vos MA, Mirams GR, Duker G, Sartipy P, de Boer TP, van Veen TA.

    J Mol Cell Cardiol. 2012 May;52(5):998-1008. Epub 2012 Feb 14.

    2912
  • Non-specific protein-DNA interactions control I-CreI target binding and cleavage.

    Molina R, Redondo P, Stella S, Marenchino M, D'Abramo M, Gervasio FL, Charles Epinat J, Valton J, Grizot S, Duchateau P, Prieto J, Montoya G.

    Nucleic Acids Res. 2012 Apr 11. [Epub ahead of print]

    2892
  • Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases.

    Daboussi F, Zaslavskiy M, Poirot L, Loperfido M, Gouble A, Guyot V, Leduc S, Galetto R, Grizot S, Oficjalska D, Perez C, Delacôte F, Dupuy A, Chion-Sotinel I, Le Clerre D, Lebuhotel C, Danos O, Lemaire F, Oussedik K, Cédrone F, Epinat JC, Smith J, Dickson G, Popplewell L, Koo T, Vandendriessche T, Chuah MK, Duclert A, Duchateau P, Pâques F.

    Nucleic Acids Res. 2012 Mar 29. [Epub ahead of print]

    2890
  • Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes

    L Nalos, R Varkevisser, MKB Jonsson, MJC Houtman, JD Beekman, R van der Nagel, MB Thomsen, G Duker, P Sartipy, TP de Boer, M Peschar, MB Rook, TAB van Veen, MAG van der Heyden, MA Vos

    Br J Pharmacol. 2012 Jan;165(2):467-78. doi: 10.1111/j.1476-5381.2011.01558.x.

    2867
  • Free-Form-Fabricated Commercially Pure Ti and Ti6Al4V Porous Scaffolds Support the Growth of Human Embryonic Stem Cell-Derived Mesodermal Progenitors

    G. M. de Peppo,  A. Palmquist,  P. Borchardt,  M. Lennerås,  J. Hyllner, A. Snis, J. Lausmaa, P. Thomsen, 2 and C. Karlsson

    Scientific World Journal. 2012;2012:646417. Epub 2012 Jan 4.

    2850
  • Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue

    Jane Synnergren, Caroline Améen, Andreas Jansson and Peter Sartipy

    Physiol. Genomics 44:245-258, 2012. First published 13 December 2011;

    2894
  • Differential bone-forming capacity of osteogenic cells from either embryonic stem cells or bone marrow-derived mesenchymal stem cells

    Sanne K. Both, Aart A. van Apeldoorn, Jojanneke M. Jukes, Mikael C.O. Englund, Johan Hyllner, Clemens A. van Blitterswijk, Jan de Boer

    J Tissue Eng Regen Med. 2011 Mar;5(3):180-90

    2875
  • Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review

    Carl-Fredrik Mandenius, Daniella Steel, Fozia Noor, Thomas Meyer, Elmar Heinzle, Julia Asp, Sarina Arain, Udo Kraushaar, Susanne Bremer, Reiner Class, Peter Sartipy

    J Appl Toxicol. 2011 Feb 16

    2873
  • Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project

    Carl-Fredrik Mandenius, Tommy B. Andersson, Paula M. Alves, Christine Batzl-Hartmann, Petter Björquist, Manuel J.T. Carrondo, Christophe Chesne, Sandra Coecke, Josefina Edsbagge, J. Magnus Fredriksson, Jörg C. Gerlach, Elmar Heinzle, Magnus Ingelman- Sundberg, Inger Johansson, Barbara Küppers-Munther, Ursula Müller-Vieira, Fozia Noor and Katrin Zeilinger

    2011, ATLA 39, 1-25

    2871
  • Concise Review: Human Pluripotent Stem Cell-Based Models for Cardiac and Hepatic Toxicity Assessment

    Peter Sartipy, Petter Björquist

    Stem Cells. 2011 March 23

    2869
    • X

    Enter your email address:

    Delivered by FeedBurner